The KAYAKU spirit represents Nippon Kayaku Group's corporate
vision - the ultimate goal of all its corporate activities.
We fulfill our social responsibilities as part of our corporate efforts to realize
the KAYAKU spirit. These efforts are based on the standards of conduct
articulated in the Group Action Guidelines and in the Nippon Kayaku Group
Charter of Conduct and Code of Conduct.
What's New
- 2023/10/19
- Updated information of sustainability
- 2023/10/18
- Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
- 2023/09/25
-
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.
- 2022/11/16
-
Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg “CTNK” ,an anti-VEGF humanized monoclonal antibody
- 2021/06/30
-
New Late-Breaking Data at The American Diabetes Association Show GlycoMark May Be an Effective Test for COVID-19 Severity
